Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...

In November, six months after KJ’s debut, top Food and Drug Administration officials Marty Makary and Vinay Prasad published ...

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

The U.S. Patent and Trademark Office has accepted a groundbreaking patent from Dei BioPharma Ltd., marking a significant milestone in the treatment of sickle cell disease.Dei BioPharma, a Ugandan ...